Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles

Patent metadata

Field	Value
Publication number	US-9549976-B1
Application number	US-201314081629-A
Country	US
Kind code	B1
Filing date	Nov 15, 2013
Priority date	Nov 16, 2012
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

The invention relates to virus-like particles of bacteriophage MS2 (MS2 VLPs) displaying peptide epitopes or peptide mimics of epitopes of Nipah Virus envelope glycoprotein that elicit an immune response against Nipah Virus upon vaccination of humans or animals. Affinity selection on Nipah Virus-neutralizing monoclonal antibodies using random sequence peptide libraries on MS2 VLPs selected peptides with sequence similarity to peptide sequences found within the envelope glycoprotein of Nipah itself, thus identifying the epitopes the antibodies recognize. The selected peptide sequences themselves are not necessarily identical in all respects to a sequence within Nipah Virus glycoprotein, and therefore may be referred to as epitope mimics VLPs displaying these epitope mimics can serve as vaccine. On the other hand, display of the corresponding wild-type sequence derived from Nipah Virus and corresponding to the epitope mapped by affinity selection, may also be used as a vaccine.

First claim

What is claimed is:

1. A population of virus-like particles (VLPs) produced by a method comprising:
(a) providing a population of VLPs that have been expressed by a prokaryote, wherein each of said VLPs comprises a coat polypeptide of a MS2 or PP7 bacteriophage, wherein said coat polypeptide is modified by insertion of an immunogenic heterologous peptide of Nipah Virus within the amino acid sequence of said coat polypeptide at a site corresponding to the A-B loop, wherein said heterologous peptide is displayed on said VLPs and said VLPs optionally encapsidate said bacteriophage mRNA; and
(b) wherein said heterologous peptide comprises at least one peptide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38; and
(c) exposing said population of VLPs obtained in step (a) to Nipah Virus-neutralizing antibodies to bind to said VLPs, wherein said bound VLPs are isolated.

2. A population of VLPs according to claim 1 produced by repeating said method from 2 to 4 times.

3. A virus-like particle comprising a coat polypeptide of a MS2 or PP7 bacteriophage wherein said coat polypeptide is modified by insertion of an immunogenic heterologous peptide of Nipah Virus within the amino acid sequence of said coat polypeptide at a site corresponding to the A-B loop, wherein said heterologous peptide is displayed on said VLP and said VLP optionally encapsidates said bacteriophage mRNA, and said coat polypeptide of said bacteriophage is a single chain dimer comprising an upstream and downstream subunit, and wherein said heterologous peptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37 or SEQ ID NO: 38.

4. The VLP according to claim 3 , wherein said bacteriophage is PP7.

5. The VLP according to claim 3 , wherein said bacteriophage is MS2.

6. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13.

7. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 27.

8. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5.

9. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37 or SEQ ID NO: 38.

10. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32 or SEQ ID NO: 33.

11. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.

12. The VLP according to claim 3 , wherein said heterologous peptide is selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22 or SEQ ID NO: 23.

13. The VLP according to claim 3 , wherein said heterologous peptide is peptide is selected from the group consisting of: SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33 or SEQ ID NO: 34.

14. The VLP according to claim 3 , wherein said heterologous peptide is SEQ ID NO: 19.

15. A virus-like particle according to claim 3 expressed by a prokaryote.

16. An immunogenic composition comprising a virus-like particle of claim 3 .

17. A diagnostic assay or kit comprising a virus-like particle of claim 3 .

18. A vaccine composition comprising an immunogenic composition according to claim 16 .

Assignees

• Peabody David S
• Chackerian Bryce
• Ashley Carlee
• Carnes Eric
• Negrete Oscar
• Stc Unm
• Sandia Corp

Inventors

• Peabody David S
• Chackerian Bryce
• Ashley Carlee
• Carnes Eric
• Negrete Oscar

Classifications

• G01N33/56983 Primary

  Viruses · CPC title

• A61K39/155 Primary

  Paramyxoviridae, e.g. parainfluenza virus · CPC title

• A61K2039/5258

  Virus-like particles · CPC title

• A61K39/12

  Viral antigens · CPC title

• C12N2760/18234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title